This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Kalpaktsoglou, P. K. Articles by Good, R. A. Search for Related Content PubMed PubMed Citation Articles by Kalpaktsoglou, P. K. Articles by Good, R. A.

Effect of Pertussis Antigen and Cyclophosphamide on Myeloma Tumor¹

Pediatric Research Laboratories of the Variety Club Heart Hospital, University of Minnesota, Minneapolis, Minnesota 55455 [P.K.K., R.A.G.], and Maternity Hospital Marika Eliadi, Athens, Greece [P.K.K.]

Cyclophosphamide treatment and a combination of pertussis vaccine and cyclophosphamide treatment of transplanted mouse myeloma have been compared. Both treatments reduced mortality from the transplanted cancer. The combination of pertussis vaccine plus cyclophosphamide, although permitting a higher early mortality, resulted in a lower overall mortality. It also markedly reduced chances of a late runting and wasting syndrome accompanying late mortality observed in mice treated with cyclophosphamide alone. Neither treatment influenced cellular or humoral immune reactions when they were evaluated 200 to 250 days after treatment.

¹ Aided by grants from the American Cancer Society, the American Heart Association, and the National Foundation March of Dimes and USPHS Grants AI-00292, AI-00798, and AI-08677.

² Associate Professor of Pediatrics, Medical School of Athens University, and Director of Department of Neonatal Immunobiology at Maternity Hospital Marika Eliadi, Athens, Greece. At present, Special Research Fellow, University of Minnesota, Minneapolis, Minn. 55455.

³ American Legion Memorial Heart Research Professor of Pediatrics and Microbiology, Regents' Professor, University of Minnesota, Minneapolis, Minn. 55455.

Received 6/ 4/70. Accepted 8/ 5/70.